A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.
← catalyst calendarSponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Basic science
Enrollment
72actual
Sites
42
Countries
Japan, Singapore, South Korea +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-05-17 | actual | When the study began enrolling |
| Primary completion | 2025-11-21 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-21 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
- Drug: Bemarituzumab
- Drug: CAPOX
- Drug: SOX
- Drug: Nivolumab
Primary outcomes
what the primary-completion date above is the date OFPart 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT)
measured Day 1 up to Day 21
Part 1: Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)
measured Day 1 to end of treatment (up to approximately 1 year)
Part 2: Objective Response (OR) as per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)
measured Up to 30 Months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed